LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.

According to TipRanks.com, Wright is a 5-star analyst with an average return of 12.3% and a 61.9% success rate. Wright covers the Healthcare sector, focusing on stocks such as Phibro Animal Health, ...

LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.

Eli Lilly's stock price shot up by 2.89% on a massive trading volume of 21.27 billion, signaling strong investor interest.

Eli Lilly closed at $1.87, ranked 34th in trading volume on July 22, 2025. BMO Capital remains bullish, reiterating a buy ...

Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, ...

The program was formally launched July 28 at a signing ceremony at Wake Tech’s Beltline Education Center in Raleigh. Leaders ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

The healthcare sector, including managed-care firms and drug powerhouses, is vastly underperforming the S&P 500 index. Here ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Therini Bio, Inc., a clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular dysfunction today announced that the first patient has ...

The market value of the company surpassed the size of Denmark’s entire economy last year and, for a period, Novo Nordisk was ...